[{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase I","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase I","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Genta Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase I","graph3":"Genta Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genta Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genta Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Genta Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Genta Incorporated","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Genta Incorporated"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase I","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Jefferies"}]
Find Clinical Drug Pipeline Developments & Deals for Tesetaxel
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
